Chronic obstructive pulmonary disease (COPD) is a lung disease characterized by breathing difficulty due to airflow blockage. COPD includes conditions such as, chronic bronchitis, inflammation of bronchial tubes, and emphysema, which occurs when the alveoli are gradually destroyed. COPD damage is irreversible and current treatments are mostly palliative and aim to minimize further damage.
Cell therapy utilizing mesenchymal stem cells (MSCs) that feature paracrine activities may stimulate endogenous stem cells, assisting them in differentiating into alveolar epithelium, thereby leading to lung damage repair and to improved pulmonary function. In addition, the anti-inflammatory effects of systemically administered MSCs may decrease inflammation, resulting in improved lung function and quality of life.